When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

GLP-1 drugs have become all the rage for weight loss, with sales for drugs like Novo Nordisk's Ozempic and Eli Lilly's (NYSE: ...

All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly ...

Novo Nordisk's phase 1b/2a clinical trial results revealed that their investigational drug, amycretin, led to an average ...

Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed. The ...

Investing in stocks with high valuations isn't necessarily a bad decision, but it's something to be done deliberately and ...

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Exxon Mobil ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new Novo Nordisk drug ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly recently updated Q4 revenue guidance ... was Lilly's specific guidance related to its blockbuster GLP-1 drugs, Mounjaro and Zepbound. For the fourth quarter, Lilly calls for revenue ...